Connor, Clark & Lunn Investment Management Ltd.

Position in XERS — Xeris Biopharma Holdings, Inc.

CIK 1596800 VANCOUVER, A1

Back to XERS Full portfolio

Position in XERS

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$2,364,225

-$5,946,507 QoQ

Shares Held

407,625

-61.5% QoQ

Ownership

0.236%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2022

8 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in XERS Over Time

Shares Held

Position Value (USD)

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $123,963,967 across 16 Drug Manufacturers - Specialty & Generic names. XERS ranks #9 (1.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	KNSA	Kiniksa Pharmaceuticals International, plc	649,629	$31,279,636
2	ZTS	Zoetis Inc.	187,329	$22,144,161
3	NBIX	Neurocrine Biosciences Inc	153,755	$20,255,683
4	TEVA	Teva Pharmaceutical Industries Ltd	471,891	$14,213,356
5	AMLX	Amylyx Pharmaceuticals, Inc.	868,325	$12,069,717
6	IRWD	Ironwood Pharmaceuticals Inc	1,835,424	$6,442,338
7	EBS	Emergent BioSolutions Inc.	648,377	$5,381,529
8	RDY	Dr Reddys Laboratories Ltd	382,976	$5,304,217

All Filings in XERS

Export CSV

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,364,225	407,625	-61.5%	Shares	Sole	2026-05-11
2025-12-31	$8,310,732	1,058,692	-37.7%	Shares	Sole	2026-02-10
2025-09-30	$13,827,881	1,698,757	+38.3%	Shares	Sole	2025-11-13
2025-06-30	$5,734,568	1,227,959	+108.3%	Shares	Sole	2025-08-07
2025-03-31	$3,236,195	589,471	+244.1%	Shares	Sole	2025-05-12
2024-12-31	$580,815	171,332	+106.2%	Shares	Sole	2025-02-10
2024-09-30	$236,857	83,108	+187.6%	Shares	Sole	2024-11-08
2022-03-31	$73,976	28,897	—	Shares	Sole	2022-05-12
No filing history on record for this holder in this stock.